CRISPR Therapeutics Ltd

CRSP

Equity

ISIN CH0334081137 / Valor 33408113

NASDAQ (2025-11-17)

USD 55.32+5.31%

CRISPR Therapeutics Ltd
UMushroom community rating:

4.10 16 votes No rating yet

NegativeNeutralPositive

About company

CRISPR Therapeutics Ltd is a biotechnology company that focuses on developing gene-editing therapies. One of their key products is CASGEVY™, a CRISPR/Cas9 gene-edited therapy developed in collaboration with Vertex Pharmaceuticals Incorporated, which has received approval in some countries for treating patients with sickle cell disease or transfusion-dependent beta thalassemia. The company's innovative approach to gene editing has the potential to revolutionize the treatment of genetic diseases, offering hope to patients with previously untreatable conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Cash Position

As of December 31, 2024, CRISPR Therapeutics Ltd held $1,903.8 million in cash, cash equivalents, and marketable securities, up from $1,695.7 million at the end of 2023. This increase reflects substantial proceeds from a February 2024 registered direct offering and milestone payments from Vertex Pharmaceuticals.

Proceeds and Financial Growth

The rise in cash reserves was primarily driven by a $280.0 million registered direct offering in February 2024, along with milestone payments received from Vertex Pharmaceuticals related to their licensing and collaboration agreements. Additionally, proceeds from the ATM facility contributed to the enhanced financial position.

Outlook for 2025

CRISPR Therapeutics Ltd anticipates 2025 to be a catalyst-rich year with significant advancements expected in the launch of CASGEVY®, expansion of treatment centers, and updates on various clinical trials. The strong financial foundation supports the company's ongoing and upcoming initiatives across its pipeline.

Summarized from source with an LLMView Source

Key figures

17.1%1Y

-4.02%3Y

-49.0%5Y

Performance

62.7%1Y

58.2%3Y

60.8%5Y

Volatility